Reviewing Haemonetics Corporation (HAE)’s and Endologix Inc. (NASDAQ:ELGX)’s results

Both Haemonetics Corporation (NYSE:HAE) and Endologix Inc. (NASDAQ:ELGX) are each other’s competitor in the Medical Instruments & Supplies industry. Thus the compare of their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Haemonetics Corporation 951.84M 4.61 46.06M 0.92 113.51
Endologix Inc. 165.78M 0.36 68.28M -0.81 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.


Table 2 provides Haemonetics Corporation and Endologix Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Haemonetics Corporation 4.84% 2.9% 1.7%
Endologix Inc. -41.19% -126% -19.9%

Volatility and Risk

Haemonetics Corporation’s 1.1 beta indicates that its volatility is 10.00% more volatile than that of S&P 500. Competitively, Endologix Inc.’s 53.00% volatility makes it less volatile than S&P 500, because of the 0.47 beta.


Haemonetics Corporation has a Current Ratio of 2.9 and a Quick Ratio of 2.1. Competitively, Endologix Inc.’s Current Ratio is 1.6 and has 1 Quick Ratio. Haemonetics Corporation’s better ability to pay short and long-term obligations than Endologix Inc.

Institutional & Insider Ownership

The shares of both Haemonetics Corporation and Endologix Inc. are owned by institutional investors at 0% and 75.8% respectively. Insiders owned 0.7% of Haemonetics Corporation shares. On the other hand, insiders owned about 0.1% of Endologix Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Haemonetics Corporation -2.87% -9.46% -7.01% 11.48% 84.23% 79.41%
Endologix Inc. -23.13% -50.8% -66.95% -89.34% -87.86% -87.77%

For the past year Haemonetics Corporation had bullish trend while Endologix Inc. had bearish trend.


Haemonetics Corporation beats Endologix Inc. on 11 of the 11 factors.

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products. The company also offers hospital products comprising TEG thrombelastograph hemostasis analyzer system, a blood diagnostic instrument that measure a patientÂ’s hemostasis or the ability to form and maintain blood clots; Cell Saver system, a surgical blood salvage system for cardiovascular surgeries; and OrthoPAT surgical blood salvage systems for orthopedic procedures. In addition, it offers SafeTrace Tx, a software solution that manages blood product inventory and transfusion, as well as performs patient cross-matching; and BloodTrack suite of solutions for managing, tracking, and controlling blood products from the hospital blood center through to transfusion to the patient. The company markets and sells its products to biopharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations, and national health organizations through its direct sales force, as well as independent distributors. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. The company also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, it offers proximal aortic extensions and limb extensions, which attach to the main body of its EVAR device, allowing physicians to customize it to fit the patientÂ’s anatomy; and accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, inflation devices, and snares. The company offers its EVAR products under Powerlink System, IntuiTrak, AFX, VELA Proximal Endograft brand names; and EVAS products under the Nellix EVAS system brand name. It sells its products through direct sales force, network of agents, and independent distributors or agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.